Entrada Therapeutics Inc. Common Stock (TRDA)
TurnaroundFairStock Score: 33/100 — RISKY
Key Financials
| Current Price | $4.41 |
| Market Cap | $172M |
| P/E Ratio | -1.11 |
| ROE | -54.1% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At $4.86 on 2026-10-13, Entrada is a speculative clinical-stage biotech, not a classic Buffett compounder. The filed figures show violent swings: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $898,000 and net loss was $42.8M, or diluted EPS -$1.01. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $875,000 and net loss was $39.7M, or diluted EPS -$0.95. In fiscal year 2025, revenue was $25.4M and net loss was $143.8M, or diluted EPS -$3.47. That contrasts with fiscal year 2024, when revenue was $210.8M and net income was $65.6M, or diluted EPS $1.68, and fiscal year 2023, when revenue was $129.0M and net loss was $6.7M, or diluted EPS -$0.20. The Lynch category is TURNAROUND—loss in latest year after earlier profits—and I can see why.
In plain English: Entrada Therapeutics is a clinical-stage biotech company working on genetic medicines for nerve/muscle and inherited eye diseases. It is not making steady money right now: revenue has shrunk sharply and losses are large. At $4.86, the stock looks cheap on its accounting value, but the weak business trends make it a speculative situation rather than a stable bargain.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer